Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways
Future Medicinal Chemistry · 03.06.2026 · 18 (11) · 1443-1463
DOI: 10.1080/17568919.2026.2658831 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 21.04.2026. Verfasst von Raju Ninave und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Heterocyclic Compounds, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 143 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Heavy Water Board, DAE, Mumbai, India.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, driving uncontrolled myeloid proliferation. Although BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs) have significantly improved CML management, challenges such as drug resistance, intolerance, and long-term adverse effects persist. To overcome these limitations, recent research has focused on developing next-generation TKIs and alternative molecular scaffolds capable of bypassing resistance mechanisms. Among these, five-membered heterocyclic compounds have gained considerable attention due to their structural diversity, favorable pharmacokinetic properties, and ability to interact with multiple biological targets. Several clinically relevant agents, including dasatinib, ponatinib, and asciminib, incorporate such heterocyclic frameworks, highlighting their therapeutic significance. In addition to direct inhibition of BCR::ABL1, these compounds can modulate key signaling pathways involved in CML progression, such as PI3K/Akt, MAPK, and JAK/STAT. This review explores the chemical diversity, molecular interactions, and therapeutic potential of five-membered heterocyclic compounds in CML. Overall, these scaffolds represent promising candidates for developing more effective and less toxic treatment strategies, improving long-term patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India.
ORCID-Profile: Raju Ninave, Aman Mourya, Navnit Prajapati
Förderung
- Heavy Water Board, DAE, Mumbai, India
Zitieren
APA
Ninave, R., Mourya, A., & Prajapati, N. (2026). Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways. Future Medicinal Chemistry, 18(11), 1443-1463. https://doi.org/10.1080/17568919.2026.2658831
Vancouver
Ninave R, Mourya A, Prajapati N. Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways. Future Medicinal Chemistry. 2026;18(11):1443-1463. doi:10.1080/17568919.2026.2658831
BibTeX
@article{Ninave2026,
author = {Ninave, Raju and Mourya, Aman and Prajapati, Navnit},
title = {Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways},
journal = {Future Medicinal Chemistry},
year = {2026},
volume = {18},
number = {11},
pages = {1443--1463},
doi = {10.1080/17568919.2026.2658831}
}
EUVIMED